Global Virtual Clinical Trials Market Industry Analysis and Forecast Report Released
Reportlinker.com has announced the release of the report "Global Virtual Clinical Trials Market By Study Type, By Indication, By Region, Industry Analysis and Forecast, 2020 – 2026."
The market is significantly driven by growth in R&D activities, the growing digitization in healthcare, and the adoption of telehealth. Virtual Clinical Trials or remote/decentralized trails are a relatively new but still underused technique of carrying out clinical research taking complete benefit of technologies like apps, online social interaction platforms, and electronic monitoring tools. Advances in technology, collaborations between clinical research companies, biotechnology companies, and pharmaceutical and support initiatives from governments, are expected to boost the market. The market’s size is expected to reach $10 billion by 2026, rising at a market growth of 6. 5% CAGR during the forecast period.
For more of report’s analysis, click here.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
